top of page
Sinking Prospects: Cadiz, Inc. Faces Financial and Dilution Challenges
Summary: Baoro Research is initiating coverage on Cadiz, Inc. with a " Sell " recommendation, setting a target price of $2.90 per...
Nov 5, 20243 min read
Assessing the Impact of EyePoint Pharmaceutical's Recent Equity Issuance
Summary On October 28, 2024, EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced an underwritten public offering of $100 million in...
Oct 30, 20243 min read
MacroGenics and TerSera: A Strategic Acquisition with Significant Risks
Summary: On October 22, 2024, MacroGenics announced an agreement with TerSera Therapeutics for the acquisition of global rights to...
Oct 24, 20245 min read
bottom of page